市場調查報告書

全球過敏治療市場:成長,趨勢,及預測(2020年∼2025年)

Allergy Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921868
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
全球過敏治療市場:成長,趨勢,及預測(2020年∼2025年) Allergy Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年03月01日內容資訊: 英文 120 Pages
簡介

全球過敏治療市場增長的關鍵因素包括過敏治療負擔的增加,製造商對開發新過敏治療的投資的增加以及自我藥物治療的重要性日益增加。此外,皮下免疫療法(SCIT)是最常用的過敏性免疫療法,並且具有高增長率。越來越多的免疫療法批准是市場增長的主要動力。

本報告提供全球過敏治療市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各類型·治療·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 自我用藥的重要性日益增加
    • 全球食物過敏的發生率在增加
    • 增加製造商對開發新的過敏療法的投資
  • 市場阻礙因素
    • 生物相似藥的使用的偏好的高漲
    • 患者缺乏對過敏免疫療法(AIT)的認識
  • 波特的五力分析

第5章 市場區隔

  • 各類型
    • 眼的過敏
    • 鼻炎
    • 氣喘
    • 皮膚過敏
    • 食物過敏
    • 其他
  • 不同治療
    • 抗過敏藥
    • 免疫療法
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • ALK-Abello A/S
    • Allergy Therapeutics
    • Sanofi SA
    • Allergan Plc.
    • Merck KGaA (Allergopharma)
    • F. Hoffmann-La Roche Ltd. (Genentech Inc.)
    • Stallergenes Greer plc
    • Johnson & Johnson
    • GlaxoSmithKline plc
    • Leti Pharma

第7章 市場機會及今後趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 67344

The major factors for the growth of the allergy treatment market include the increasing burden of various types of allergies, increased investment by the manufacturers on the development of novel allergic treatments and rising importance for self-medication.

The rising cases of allergies are expected to increase the demand of allergy immunotherapy, leading to the high growth of the market over the forecast period. According to the International Study of Asthma and Allergies in Childhood (ISAAC), about 22.1% of young children aged between 13 and 14 years are affected by hay fever, which was globally published in World Allergy Week 2016 fact sheet. As per the data published by the American College of Allergy, Asthma & Immunology, allergies are the sixth leading cause of chronic illness in the United States, with an annual cost in excess of USD 18 billion, and more than 50 million Americans suffer from allergies each year. There is an increase in the number of people suffering from food allergies among both children and adults, globally. Hence, the increasing burden of allergic diseases is expected to aid the demand for allergy treatment.

Key Market Trends

Subcutaneous Immunotherapy (SCIT) is Expected to Register a High Growth Rate

The subcutaneous immunotherapy (SCIT), is the most commonly used and most effective form of allergy immunotherapy and it is the only treatment available that actually changes the immune system, making it possible to prevent the development of new allergies and asthma. The rising approval of immunotherapy is the major factor driving the growth of the market. For instance, recently, in 2018, one of the major market players, Stallergenes Greer received approval from the United States Food and Drug Administration (FDA) for the extension of the indication for Oralair, an allergy immunotherapy sublingual tablet, to treat patients ages 5 to 9 with grass pollen-induced allergic rhinitis. Furthermore, governments are taking initiatives to increase the awareness about allergies among the population, for instance recently, in January 2018, the Ministry and the Japanese Society of Allergology opened a dedicated website about allergies. Thus, owing to the rising burden of allergies and awareness among the population the market is expected to witness high growth.

North America is Expected to Dominate the Market

According to an article by Ruchi Gupta et al. published in JAMA Network Open Journal, an estimated 10.8% were food allergic at the time of the survey, whereas nearly 19% of adults believed that they were food allergic. Nearly half of food-allergic adults had at least 1 adult-onset food allergy, and 38% reported at least 1 food allergy-related emergency department visit in their lifetime.

This prevalence is very high. However, the United States has a very developed healthcare System. It also invests large amounts into research and development. Hence, US healthcare has the ability to provide treatment to nearly all of its popualtion. Hence the US allergy treatment market is expected to cover a large share of the market.

Competitive Landscape

The majority of the allergy treatment products are being manufactured by the global key players. The market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness and this has also helped the market to grow.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 The Increasing Importance for Self-medication
    • 4.2.2 Increase in Incidence of Food Allergies Across the Globe
    • 4.2.3 Rising Investments by the Manufacturers on the Development of Novel Allergic Treatments
  • 4.3 Market Restraints
    • 4.3.1 Rise in Preference Towards the Use of Biosimilars
    • 4.3.2 Low Awareness of Allergy Immunotherapy (AIT) Among Patients
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Eye allergy
    • 5.1.2 Rhinitis
    • 5.1.3 Asthma
    • 5.1.4 Skin Allergy
    • 5.1.5 Food Allergies
    • 5.1.6 Other Allergies
  • 5.2 By Treatment
    • 5.2.1 Anti-Allergy Drugs
      • 5.2.1.1 Antihistamines
      • 5.2.1.2 Corticosteroids
      • 5.2.1.3 Decongestants
      • 5.2.1.4 Other Drugs
    • 5.2.2 Immunotherapy
      • 5.2.2.1 Sub-cutaneous Immunotherapy (SCIT)
      • 5.2.2.2 Sub-Lingual Immunotherapy (SLIT)
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 ALK-Abello A/S
    • 6.1.2 Allergy Therapeutics
    • 6.1.3 Sanofi SA
    • 6.1.4 Allergan Plc.
    • 6.1.5 Merck KGaA (Allergopharma)
    • 6.1.6 F. Hoffmann-La Roche Ltd. (Genentech Inc.)
    • 6.1.7 Stallergenes Greer plc
    • 6.1.8 Johnson & Johnson
    • 6.1.9 GlaxoSmithKline plc
    • 6.1.10 Leti Pharma

7 MARKET OPPORTUNITIES AND FUTURE TRENDS